INS and obesity disorder: Thus, the absence of systemic effects in our model likely reflects the localised actions of eplerenone, offering targeted renal protection through anti‐inflammatory and anti‐fibrotic pathways, while leaving broader metabolic and haemodynamic mechanisms of obesity, such as sympathetic activation, adipokine imbalance and insulin resistance, unaffected in the short term.